Liontrust Investment Partners LLP filed a Schedule 13D with the SEC on November 2, 2026, disclosing beneficial ownership of 5,081,403 shares of MaxCyte, Inc. common equity as of October 30, 2026.

Key Highlights

  • Beneficial ownership: Liontrust Investment Partners LLP reported aggregate beneficial ownership of 5,081,403 shares of MaxCyte, Inc. equity, representing 4.9235% of the class.
  • Sole voting and dispositive power: All 5,081,403 shares are held with sole voting power and sole dispositive power; shared voting and shared dispositive power are each reported as 0.
  • Triggering event date: The date of the event requiring the filing is reported as October 30, 2026, when a sell transaction of 112,919 shares at a trade price of 1.56814936 was executed.
  • Recent purchases: Three buy transactions on October 14, 2026, totaling 138,139, 175,694, and 43,113 shares, respectively, were all executed at a trade price of 1.26072563.
  • Prior sell activity: Multiple sell transactions occurred between August 6, 2026, and October 7, 2026, at prices ranging from approximately 1.04626808 to 1.26752510 per share.
  • Filer identity: The reporting person is Liontrust Investment Partners LLP, an investment firm organized in the United Kingdom, located at 2 Savoy Court, London, WC2R 0EZ.
  • Source of funds: The filing lists the source of funds code as "OO," indicating other sources, with Item 3 stating "N/A."

Liontrust's Schedule 13D Position in MaxCyte as of October 30, 2026

According to the Schedule 13D filing signed by Jasmine Purohit, Compliance Executive, on November 2, 2026, Liontrust Investment Partners LLP holds 5,081,403 shares of MaxCyte, Inc. equity, representing 4.9235% of the outstanding class. The filing identifies CUSIP number 57777K106 and names MaxCyte, Inc. as the issuer, with principal executive offices at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850. The filing does not identify a ticker symbol or exchange on its cover page.

The filing discloses a series of transactions between August 6, 2026, and October 30, 2026. Sell transactions occurred on August 6, 2026 (104,321 shares at 1.10126602), and across multiple dates in September 2026 at prices between approximately 1.14991057 and 1.26752510, with a further small sell on October 7, 2026, of 3,111 shares at 1.04626808. Three buy transactions on October 14, 2026, covered 138,139, 175,694, and 43,113 shares, all at 1.26072563. The triggering event for the 13D filing was a sell on October 30, 2026, of 112,919 shares at 1.56814936.

The filing states the purpose of the transaction under Item 4 as "The acquisition by any person of additional securities of the issuer, or the disposition of securities of the issuer." No contracts, arrangements, or understandings with respect to MaxCyte securities are reported, and no exhibits are listed. The filing also states that Liontrust Investment Partners LLP has not, during the last five years, been convicted in a criminal proceeding or been a party to a civil proceeding of a judicial or administrative body resulting in a judgment, decree, or final order of the type described under Items 2(d) or 2(e).

What Was Disclosed

Liontrust Investment Partners LLP filed a Schedule 13D reporting 5,081,403 shares, or 4.9235%, of MaxCyte, Inc. equity as of October 30, 2026, with sole voting and dispositive power over all reported shares, and disclosing a series of buy and sell transactions spanning August through October 2026.